JW Holdings Corporation (KRX:096760)
3,670.00
+120.00 (3.38%)
At close: Nov 26, 2025
JW Holdings Revenue
JW Holdings had revenue of 244.09B KRW in the quarter ending September 30, 2025, with 7.77% growth. This brings the company's revenue in the last twelve months to 935.51B, up 1.06% year-over-year. In the year 2024, JW Holdings had annual revenue of 887.71B, down -4.35%.
Revenue (ttm)
935.51B
Revenue Growth
+1.06%
P/S Ratio
0.27
Revenue / Employee
7.37B
Employees
127
Market Cap
253.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 887.71B | -40.36B | -4.35% |
| Dec 31, 2023 | 928.07B | 63.54B | 7.35% |
| Dec 31, 2022 | 864.54B | 75.60B | 9.58% |
| Dec 31, 2021 | 788.94B | 7.42B | 0.95% |
| Dec 31, 2020 | 781.51B | 53.43B | 7.34% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |